News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hyperion Therapeutics Release: HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy



11/12/2012 7:38:59 AM

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the Presidential Plenary Session I of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver MeetingĀ®), in Boston, MA.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES